Skip to main content

Advertisement

We're creating a new version of this page. See preview

  • Research
  • Open Access

Towards a comprehensive Plasmodium falciparum merozoite cell surface and secreted recombinant protein library

Malaria Journal201413:93

https://doi.org/10.1186/1475-2875-13-93

©  Zenonos et al.; licensee BioMed Central Ltd. 2014

  • Received: 12 December 2013
  • Accepted: 7 March 2014
  • Published:

Abstract

Background

Plasmodium falciparum is the aetiological agent for malaria, a deadly infectious disease for which no vaccine has yet been licensed. The proteins displayed on the merozoite cell surface have long been considered attractive vaccine targets because of their direct exposure to host antibodies; however, progress in understanding the functional role of these targets has been hindered by technical challenges associated with expressing these proteins in a functionally active recombinant form. To address this, a method that enables the systematic expression of functional extracellular Plasmodium proteins was previously developed, and used to create a library of 42 merozoite proteins.

Methods

To compile a more comprehensive library of recombinant proteins representing the repertoire of P. falciparum merozoite extracellular proteins for systematic vaccine and functional studies, genome-wide expression profiling was used to identify additional candidates. Candidate proteins were recombinantly produced and their integrity and expression levels were tested by Western blotting and ELISA.

Results

Twenty-five additional genes that were upregulated during late schizogony, and predicted to encode secreted and cell surface proteins, were identified and expressed as soluble recombinant proteins. A band consistent with the entire ectodomain was observed by immunoblotting for the majority of the proteins and their expression levels were quantified. By using sera from malaria-exposed immune adults, the immunoreactivity of 20 recombinant proteins was assessed, and most of the merozoite ligands were found to carry heat-labile epitopes. To facilitate systematic comparative studies across the entire library, multiple Plasmodium proteins were simultaneously purified using a custom-made platform.

Conclusions

A library of recombinant P. falciparum secreted and cell surface proteins was expanded by 20 additional proteins, which were shown to express at usable levels and contain conformational epitopes. This resource of extracellular P. falciparum merozoite proteins, which now contains 62 full-length ectodomains, will be a valuable tool in elucidating the function of these proteins during the blood stages of infection, and facilitate the comparative assessment of blood stage vaccine candidates.

Keywords

  • Plasmodium falciparum
  • Merozoite
  • Recombinant proteins
  • Mammalian expression system
  • Protein purification platform

Background

Plasmodium falciparum is the aetiological agent of the most deadly form of malaria, an infectious tropical disease that accounts for up to one million deaths annually[1, 2]. The vast majority of malaria fatalities (85-90%) occur in sub-Saharan Africa, primarily in pregnant women and children under the age of five[2, 3]. While anti-malarial drugs exist, the emergence of drug-resistant parasite strains remains a global health concern and no vaccine has been licensed to date.

The asexual blood stages of malaria are initiated when a form of the parasite, called a merozoite, invades, replicates and synchronously ruptures host erythrocytes[4] releasing up to 32 progeny merozoites that can invade new erythrocytes. This cyclical phase causes the recurrent fevers and chills that are characteristic of malaria infection[5]. Merozoites are ovoid cells containing apically located secretory organelles that release proteins which are required for the invasion of new erythrocytes[6, 7]. While erythrocyte invasion is a rapid process, the brief extracellular exposure of merozoites outside of their intra-erythrocytic niche places them in direct contact with host antibodies, which contribute to naturally acquired immunity to malaria[8, 9]; therefore, merozoite cell surface and secreted proteins have long been considered attractive targets for rational vaccine development.

The publication of the P. falciparum genome project in 2002[10] identified the full complement of parasite proteins but progress in understanding the function of these proteins, including those displayed on the merozoite cell surface, has been hindered by the technical difficulties in expressing Plasmodium proteins in a functionally active form[11]. Although the reasons why Plasmodium proteins are difficult to express in heterologous expression systems are not clear, several protein characteristics, such as high molecular mass (>60 kDa), presence of export motifs, and atypical signal peptide sequences negatively impact recombinant expression[12]. In addition, the remarkably high (~80%) A + T content of parasite genes can result in long stretches of repetitive amino acids[13], and codons that are not frequently used by organisms popular for heterologous protein expression. Extracellular vaccine candidates, in particular, present an additional challenge because they often require structurally critical disulfide bonds for correct folding and contain transmembrane domains that make them difficult to solubilize in detergents that retain their native conformation[14–16].

Despite these challenges, recombinant expression of Plasmodium proteins has been attempted in a number of expression systems[12, 17] ranging from bacteria[18], yeast[14, 19], Dictyostelium discoideum[20], plants and algae[21, 22] to mammalian cells[23, 24] and cell-free systems[13]. Among them, Escherichia coli is the most popular[17], but the systematic expression of functional P. falciparum proteins remains difficult, with success rates as low as just 6%[25], and often requires subsequent laborious and complex refolding procedures with uncertain outcomes[26]. Consequently, the functional characterization of extracellular parasite proteins has typically been restricted to smaller subfragments that can be expressed rather than the full-length protein or entire ectodomain, which is more likely to be representative of the native protein.

The development of a standardized method to express large panels of P. falciparum cell surface and secreted proteins in their native conformation would enable comprehensive protein libraries to be systematically screened in parallel so that direct comparisons between antigens can be made in functional assays such as vaccine screening and immuno-epidemiology studies. To achieve this, Crosnier and colleagues recently developed a method of expressing the entire ectodomains of functional recombinant Plasmodium proteins and used it to compile a large library of 42 proteins[27]. Working towards a comprehensive library of cell surface and secreted P. falciparum merozoite proteins, this manuscript describes the identification and characterization of an additional 20 proteins.

Methods

Recombinant protein design and expression

Proteins were expressed essentially as described previously[27]. Briefly, full-length secreted molecules and the entire ectodomains of membrane-embedded proteins were identified using transmembrane[28], GPI-anchor[29], and signal peptide[30] prediction software. To prevent the inappropriate addition of glycans, which are absent from Plasmodium proteins[31], all potential N-linked glycosylation sites (N-X-S/T, where X is not proline) were systematically mutated by substituting alanine for serine/threonine at these sites. Gene constructs were made by gene synthesis (GeneartAG) using sequences that were codon-optimized for expression in human cells. Protein coding sequences were flanked with unique NotI and AscI restriction sites and subcloned into a derivative of the pTT3 expression plasmid between a 5’ mouse variable κ light chain signal peptide[32], and a 3’ tag consisting of the rat Cd4 domains 3 and 4 followed by an enzymatic biotinylation sequence and a hexahistidine tag[33]. Proteins were expressed as soluble monobiotinylated proteins by transient cotransfection of HEK293E cells with the BirA biotin ligase[34] and harvested six days post transfection[35]. All expression plasmids are openly available from Addgene[36].

Parallel protein purification

His-tagged recombinant merozoite proteins were purified from spent tissue culture supernatants by using a custom-built, piston-driven, sample-loading apparatus as described previously[33]. Briefly, a 96-well His MultiTrap HP filter plate (GE Healthcare) was pre-equilibrated with binding buffer (20 mM sodium phosphate, 40 mM imidazole, 0.5 M NaCl, pH 7.4) at a flow rate of 1 mL/min. The harvested tissue culture supernatants (~200 mL for each protein) were supplemented with imidazole (10 mM) before loading each well at 1 mL/min. The plate was washed with 1.6 mL of binding buffer and proteins eluted with 0.2 mL of elution buffer (20 mM sodium phosphate, 0.4 M imidazole, 0.5 M NaCl, pH 7.4).

Enzyme-linked immunosorbent assay (ELISA)

ELISAs were performed as previously described[37]. Briefly, purified recombinant biotinylated proteins were serially diluted in PBS-T (PBS, 0.1% Tween-20) with 2% BSA, and captured on streptavidin-coated, 96-well plates (NUNC) for one hour before washing and incubating with the anti-Cd4 monoclonal antibody OX68 (1 μg/mL in PBS-T, 2% BSA) for another hour. Plates were washed and incubated with an anti-mouse IgG (Sigma) secondary antibody conjugated to alkaline phosphatase for one hour before further washes and incubation with p-nitrophenyl phosphate (Substrate 104; Sigma) at 1 mg/mL. Absorbance was measured at 405 nm on a PHERAstar plus (BMG Labtech). Concentrations were calculated by comparison to known standards.

Western blotting

Each purified recombinant protein was resolved by SDS-PAGE under reducing conditions before blotting onto Hybond-P PVDF membrane (GE Healthcare) for one hour at 30 V. Membranes were blocked with 2% BSA, in PBS-T and incubated with 0.02 μg/mL of streptavidin-HRP (Jackson Immunoresearch) diluted in PBS-T, 0.2% BSA and detected with the Supersignal West pico chemiluminescent substrate (Pierce).

Immunogenicity study

Proteins were heat treated at 80°C for 10 minutes or left untreated and immobilized on streptavidin-coated, 96-well plates (NUNC), at concentrations sufficient for complete saturation of the available binding surface/well (as determined by ELISA). Following three washes in PBS-T, plates were incubated with pooled sera from malaria-exposed Malawian adults or malaria-naïve UK individuals at a 1:1,000 dilution in PBS-T, 2% BSA followed by an alkaline phosphatase-conjugated anti-human IgG secondary antibody (Sigma) and detected as above.

Results

Identification of candidate Plasmodium falciparum merozoite cell surface and secreted proteins

With the aim of expanding an existing recombinant P. falciparum merozoite cell surface and secreted protein library, publicly available, genome-wide transcription microarray data of P. falciparum intra-erythrocytic stages were analysed[38, 39]. To compile a list of merozoite extracellular proteins with possible roles in erythrocyte invasion, the transcription profiles of four well-established P. falciparum merozoite ligands (RH5, AMA1, EBA140, EBA175) that have all been previously implicated in erythrocyte invasion were examined[11, 38–41]. It was observed that they all follow a similar expression pattern, passing through a minimum 20 ± 6 hours post invasion and peaking at approximately 42 ± 6 hours after invasion[38, 39]. Of the 465 candidate blood stage genes that showed similar expression time windows, 207 encoded a predicted signal peptide and/or a single transmembrane domain/GPI anchor[28–30], suggesting they are likely cell surface or secreted proteins. Multi-pass membrane proteins were excluded from this list because these proteins are unlikely to be expressed in a soluble, secreted form. Within the 207 candidates, 31 were already represented in the existing merozoite library[27] and another 120 were excluded because of their predicted function (e g, involvement in lipid metabolism or nuclear localization) or protein domain content (e g, RNA or DNA binding motif) following gene ontology analysis using PlasmoDB[42], and protein domain mapping using Pfam[43]; also, 42 proteins were excluded due to their large size (>1,400 amino acids). In total, this bioinformatics analysis identified 14 putative secreted or membrane-tethered merozoite proteins. To this list, other members of the MSP3[44, 45], MSP7-like[46–48] and SERA paralogous protein families[49] were added, which were not present in the existing P. falciparum merozoite recombinant protein library[27]. Finally, the available literature was scanned to identify an additional seven merozoite cell surface and secreted proteins[50, 51]. In total, 25 putative merozoite secreted or cell surface proteins were chosen for recombinant expression, two of which contained putative GPI anchors, and 23 contained no predicted membrane anchor (Table 1).
Table 1

The putative merozoite cell surface and secreted proteins that were chosen for recombinant expression

No

Name

Accession number

Type

Region targeted for recombinant expression

Exp. levels

1¥

rhoptry-associated membrane antigen (RAMA)

MAL7P1.208

GPI

Y17–S840

Medium

2

Prohibitin, putative

PF08_0006

Secreted

L20–F272

Low

3#

Conserved Plasmodium protein, unknown function

PF10_0166

Secreted

Y25–E310

High

4

GLURP

PF10_0344

Secreted

K24–I1233

Low

5

MSP3.5

PF10_0350

Secreted

A20–F710

High

6*

MSP3.6

PF10_0351

Secreted

N22–P566

Medium

7*

MSRP5

PF13_0191

Secreted

N22–I459

Medium

8*

MSRP4

MAL13P1.173

Secreted

D22–Q309

High

9¥

MSP8

PFE0120c

GPI

E26–S576

Low

10#

Conserved Plasmodium protein, unknown function

PF13_0125

Secreted

N20–S292

High

11

Conserved Plasmodium protein, unknown function

PF14_0044

Secreted

Q21–K290

N/D

12

Merozoite-associated tryptophan-rich antigen, putative

PFA0135w

Secreted

I25–K276

High

13

LCCL domain-containing protein

PFA0445w

Secreted

K22–I1029

N/D

14

SERA1

PFB0360c

Secreted

M1–V997

N/D

15¥

SERA2

PFB0355c

Secreted

E23–V1105

Medium

16

SERA3

PFB0350c

Secreted

T23–I930

Medium

17

SERA4

PFB0345c

Secreted

S26–V962

High

18

SERA5

PFB0340c

Secreted

T23–V997

High

19

SERA6

PFB0335c

Secreted

N25–V1031

Low

20¥

SERA7

PFB0330c

Secreted

Q23–V946

Low

21*

SERA9

PFI0135c

Secreted

E23–V932

Medium

22¥

Conserved Plasmodium protein, unknown function

PFA0210c

Secreted

Y24–D466

Low

23

Conserved Plasmodium protein, unknown function

PFB0475c

Secreted

L23–D446

Low

24

Cysteine-rich protective antigen (CyRPA)

PFD1130w

Secreted

D29–E362

High

25

RIPR

PFC1045c

Secreted

I20-N1086

Low

Protein sequences from 3D7 reference P. falciparum strain were truncated to remove endogenous signal peptides and sequences corresponding to GPI anchors. The region of each protein that was targeted for recombinant expression is shown. Expression levels are given as a guide only because of the significant batch-to-batch variability of transient transfection, and grouped into "high" (between 30 μM and 100 μM after purification), "medium" (1 μM and 30 μM) and "low" (0.01 μM and 1 μM). No detectable expression (N/D) was obtained for PFA0445w, PF14_0044 and SERA1.

¥ Proteins selected from[51].

* Proteins included to complete the set of proteins belonging to the MSP3, MSP7-like and SERA families.

# Proteins chosen from[50]. All other proteins were short-listed from bioinformatic analysis of transcription microarray data[38, 39]. GPI, GPI-anchored.

To design the expression constructs, the entire predicted extracellular domain was selected between the signal sequence and the GPI-anchor, if present. Any predicted N-linked glycosylation sites were systematically removed by substituting alanine for serine/threonine at these sites. Expression constructs were made by gene synthesis and codon optimized for expression in human cells. All expression plasmids are publicly available through Addgene, a not-for-profit, open access plasmid repository[36].

Expression and purification of an expanded Plasmodium falciparum merozoite protein library

All proteins were expressed in HEK293E cells as soluble fusion proteins that contained a C-terminal rat Cd4(d3 + 4)-hexahistidine tag for purification and could be optionally monobiotinylated by cotransfecting a secreted version of the E. coli BirA enzyme[33]. To purify many proteins in parallel for comparative screening, a custom-built protein purification system was employed, that enables the simultaneous purification of up to 96 His-tagged proteins, even from large (>50 mL) tissue culture volumes[33].

Following purification, recombinant proteins were quantitated by ELISA and while expression levels varied significantly between individual proteins, most were purified to micromolar levels (Table 1). Overall, detectable expression was obtained for 22 out of 25 (88%) proteins. Both GLURP and SERA6, although detected by ELISA, were expressed at levels that were too low to include in further analysis and three proteins (PF14_0044, PFA0445w, SERA1) remained undetectable by ELISA despite repeated transfections.

To assess their integrity, the recombinant proteins were resolved by SDS-PAGE, and the presence of the C-terminal biotin tag detected by Western blotting (Figure 1). A band consistent with the full-length ectodomain was obtained for 20 out of 25 proteins (80%); in some cases, smaller bands were also evident, most likely due to proteolytic processing. For SERA7 and PF08_0006, bands of ~30 and ~25 kDa were detected, respectively, suggesting complete cleavage at the C-terminus of the protein. Collectively, these observations establish the successful expression of 18/25 (72%) recombinant P. falciparum merozoite proteins at a size consistent with a full-length recombinant protein at usable amounts.
Figure 1
Figure 1

The majority of recombinant merozoite extracellular proteins are expressed at their expected size. One microgram of each purified biotinylated merozoite protein (as estimated by the absorbance at 280 nm) was resolved under reducing conditions by SDS-PAGE, blotted, and probed using streptavidin-HRP. The expected molecular mass of each recombinant protein is indicated in brackets above each lane, including the Cd4-6xHis tag (25 kDa).

Members of the recombinant merozoite protein library proteins are immunoreactive and carry heat-labile epitopes

In nature, protective antibodies largely recognize proteins in their native conformation; therefore, to examine whether the recombinant merozoite library proteins were correctly folded, their immunoreactivity against hyperimmune sera from adults living in malaria-endemic regions was tested. All 20 proteins from the library expressed at useable levels were arrayed on a streptavidin-coated, microtitre plate and their relative immunoreactivity to pooled sera from Malawian adults was compared to that from malaria-naïve individuals[52]. All but one (MSRP4) of the proteins were immunoreactive (Figure 2). Strikingly, strong immunoreactivity was observed for most of the SERA proteins, consistent with previous observations[49].
Figure 2
Figure 2

The merozoite recombinant proteins are immunoreactive against hyperimmune sera. The immunoreactivity of the recombinant P. falciparum merozoite proteins was tested using pooled sera from malaria-exposed Malawian adults (red bar) or malaria-naïve adults (green bar). The reduced immunoreactivity of immune sera to heat-denatured antigens (blue bar) demonstrates the presence of heat-labile (conformational) epitopes. All proteins except one (MSRP4) were identified as being immunoreactive as assessed by immunoreactivity >3 SD above negative control (green bar). AMA-1 and Cd4 were used as the positive and negative control, respectively. Data points are shown as mean ± s.d.; n = 3.

To demonstrate that serum antibodies were recognizing conformational epitopes within the protein library, all recombinant proteins were denatured by heat treatment before being captured via their biotin tag. For 16 of the 20 proteins (all but MSRP4, SERA7, PFA0210c, and PFB0475c) the immunoreactivity decreased significantly when the proteins were heat inactivated, establishing that the antigens contain heat-labile epitopes. These data show that the merozoite recombinant proteins are correctly folded and at least in part mimic the native protein conformation.

Discussion

The technical difficulties in expressing Plasmodium proteins in a recombinant functional form has presented difficulties both for basic malaria research and vaccine development[12]. Here, an approach based on a mammalian expression system has been utilized to significantly expand a recombinant library consisting of recombinant P. falciparum merozoite extracellular proteins from 42 to 62 members[27]. A high-throughput, custom-made purification platform was successfully used to purify recombinant proteins from large volumes of tissue culture supernatants to permit systematic comparative studies of purified antigens[33].

While the overall success rate of expression was high, consistent with previous experience of the HEK293 system[27, 53–57], a few merozoite proteins still failed to express, or were expressed at low levels. Although the genes were codon-optimized for human cells, P. falciparum proteins are unusual because they are enriched in asparagine, glutamic acid and lysine, and often contain homopolymeric stretches of amino acids. Indeed, it has been recently demonstrated that the stability of several Plasmodium proteins depends upon their association with heat shock proteins which act as molecular chaperones[58]. Therefore, recombinant protein expression in the HEK293 system could be further enhanced by the presence of Pf Hsp110c, which has been proposed to be a protein-stabilizing chaperone[58].

Using sera from malaria-immune adults, it has been shown that the expressed recombinant proteins contained heat-labile epitopes suggesting that they adopt their native conformation and are likely to be biochemically active. A number of proteins (e g, PF10_0166, PFA0135w) showed little serological response in comparison to the negative control. While these proteins may not contain epitopes present in the native protein, the possibility that the native proteins are poorly immunogenic and do not induce a strong antibody response in vivo, cannot be excluded. For example, previous studies reported that only 23% of immune sera examined contained specific serum IgG antibodies against PFA0135w, suggesting that this protein does not normally elicit strong humoral responses[59]. Interestingly, RIPR, which binds to Pf RH5[60], is also among the group of generally low responders. Pf RH5 is a high priority vaccine target as it plays an essential and universal role in erythrocyte invasion[53, 57, 61–63], yet it is poorly immunogenic in vivo[61], possibly due to its late release onto the merozoite surface during erythrocyte invasion. RIPR may be similarly masked from the host immune system, but further work with this antigen is clearly required.

Conclusion

A library of recombinant P. falciparum proteins has been expanded and characterized with the eventual aim of compiling a set that is representative of the merozoite surface. These plasmids, which are freely available to the global research community through Addgene[36], will be a valuable resource for basic research and aid the efforts to develop an effective malaria vaccine.

Declarations

Acknowledgements

This work was supported by the Wellcome Trust grant number [098051]. We thank Cécile Crosnier for helpful comments on the manuscript and Faith Osier and Kevin Marsh for malaria immune sera.

Authors’ Affiliations

(1)
Cell Surface Signalling Laboratory, Wellcome Trust Sanger Institute, Cambridge, CB10 1SA, UK
(2)
Malaria Programme, Wellcome Trust Sanger Institute, Cambridge, CB10 1SA, UK

References

  1. Murray CJL, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD: Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet. 2012, 379: 413-431. 10.1016/S0140-6736(12)60034-8.View ArticlePubMedGoogle Scholar
  2. World Health Organization: World Malaria Report: 2012. 2012, Geneva: Switzerland: Global Malaria ProgrammeGoogle Scholar
  3. Geels MJ, Imoukhuede EB, Imbault N, van Schooten H, McWade T, Troye-Blomberg M, Dobbelaer R, Craig AG, Leroy O: European vaccine initiative: lessons from developing malaria vaccines. Expert Rev Vaccines. 2011, 10: 1697-1708. 10.1586/erv.11.158.View ArticlePubMedGoogle Scholar
  4. Miller LH, Baruch DI, Marsh K, Doumbo OK: The pathogenic basis of malaria. Nature. 2002, 415: 673-679. 10.1038/415673a.View ArticlePubMedGoogle Scholar
  5. Chen Q, Schlichtherle M, Wahlgren M: Molecular aspects of severe malaria. Clin Microbiol Rev. 2000, 13: 439-450. 10.1128/CMR.13.3.439-450.2000.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Garcia CRS, de Azevedo MF, Wunderlich G, Budu A, Young JA, Bannister L: Plasmodium in the postgenomic era: new insights into the molecular cell biology of malaria parasites. Int Rev Cell Mol Biol. 2008, 266: 85-156.View ArticlePubMedGoogle Scholar
  7. Dvorak JA, Miller LH, Whitehouse WC, Shiroishi T: Invasion of erythrocytes by malaria merozoites. Science. 1975, 187: 748-750. 10.1126/science.803712.View ArticlePubMedGoogle Scholar
  8. Cohen S, McGregor IA, Carrington S: Gamma-globulin and acquired immunity to human malaria. Nature. 1961, 192: 733-737. 10.1038/192733a0.View ArticlePubMedGoogle Scholar
  9. Cohen S, Butcher GA, Crandall RB: Action of malarial antibody in vitro. Nature. 1969, 223: 368-371. 10.1038/223368a0.View ArticlePubMedGoogle Scholar
  10. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan M-S, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DMA: Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 2002, 419: 498-511. 10.1038/nature01097.View ArticlePubMedGoogle Scholar
  11. Bartholdson SJ, Crosnier C, Bustamante LY, Rayner JC, Wright GJ: Identifying novel Plasmodium falciparum erythrocyte invasion receptors using systematic extracellular protein interaction screens. Cell Microbiol. 2013, 15: 1304-1312. 10.1111/cmi.12151.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Birkholtz L-M, Blatch G, Coetzer TL, Hoppe HC, Human E, Morris EJ, Ngcete Z, Oldfield L, Roth R, Shonhai A, Stephens L, Louw AI: Heterologous expression of plasmodial proteins for structural studies and functional annotation. Malar J. 2008, 7: 197-10.1186/1475-2875-7-197.PubMed CentralView ArticlePubMedGoogle Scholar
  13. Tsuboi T, Takeo S, Iriko H, Jin L, Tsuchimochi M, Matsuda S, Han E-T, Otsuki H, Kaneko O, Sattabongkot J, Udomsangpetch R, Sawasaki T, Torii M, Endo Y: Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates. Infect Immun. 2008, 76: 1702-1708. 10.1128/IAI.01539-07.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Stowers AW, Zhang Y, Shimp RL, Kaslow DC: Structural conformers produced during malaria vaccine production in yeast. Yeast. 2001, 18: 137-150. 10.1002/1097-0061(20010130)18:2<137::AID-YEA657>3.0.CO;2-X.View ArticlePubMedGoogle Scholar
  15. Vedadi M, Lew J, Artz J, Amani M, Zhao Y, Dong A, Wasney G, Gao M, Hills T, Brokx S, Qiu W, Sharma S, Diassiti A, Alam Z, Melone M, Mulichak A, Wernimont A, Bray J, Loppnau P, Plotnikova O, Newberry K, Sundararajan E, Houston S, Walker J, Tempel W, Bochkarev A, Kozieradzki I, Edwards A, Arrowsmith C, Roos D: Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms. Mol Biochem Parasitol. 2007, 151: 100-110. 10.1016/j.molbiopara.2006.10.011.View ArticlePubMedGoogle Scholar
  16. Wright GJ: Signal initiation in biological systems: the properties and detection of transient extracellular protein interactions. Mol Biosyst. 2009, 5: 1405-1412. 10.1039/b903580j.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Fernández-Robledo JA, Vasta GR: Production of recombinant proteins from protozoan parasites. Trends Parasitol. 2010, 26: 244-254. 10.1016/j.pt.2010.02.004.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Outchkourov NS, Roeffen W, Kaan A, Jansen J, Luty A, Schuiffel D, van Gemert GJ, van de Vegte-Bolmer M, Sauerwein RW, Stunnenberg HG: Correctly folded Pf s48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice. Proc Natl Acad Sci U S A. 2008, 105: 4301-4305. 10.1073/pnas.0800459105.PubMed CentralView ArticlePubMedGoogle Scholar
  19. Tsai CW, Duggan PF, Shimp RL, Miller LH, Narum DL: Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris. J Biotechnol. 2006, 121: 458-470. 10.1016/j.jbiotec.2005.08.025.View ArticlePubMedGoogle Scholar
  20. Van Bemmelen MX, Beghdadi-Rais C, Desponds C, Vargas E, Herrera S, Reymond CD, Fasel N: Expression and one-step purification of Plasmodium proteins in Dictyostelium. Mol Biochem Parasitol. 2000, 111: 377-390. 10.1016/S0166-6851(00)00330-3.View ArticlePubMedGoogle Scholar
  21. Ghosh S, Malhotra P, Lalitha P: Expression of Plasmodium falciparum C-terminal region of merozoite surface protein (Pf MSP1 19), a potential malaria vaccine candidate, in. Plant Sci. 2002, 162: 335-343. 10.1016/S0168-9452(01)00555-6.View ArticleGoogle Scholar
  22. Gregory J a, Li F, Tomosada LM, Cox CJ, Topol AB, Vinetz JM, Mayfield S: Algae-produced Pf s25 elicits antibodies that inhibit malaria transmission. PLoS One. 2012, 7: e37179-10.1371/journal.pone.0037179.PubMed CentralView ArticlePubMedGoogle Scholar
  23. VanBuskirk KM, Sevova E, Adams JH: Conserved residues in the Plasmodium vivax Duffy-binding protein ligand domain are critical for erythrocyte receptor recognition. Proc Natl Acad Sci U S A. 2004, 101: 15754-15759. 10.1073/pnas.0405421101.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Tolia NH, Enemark EJ, Sim BKL, Joshua-Tor L: Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium falciparum. Cell. 2005, 122: 183-193. 10.1016/j.cell.2005.05.033.View ArticlePubMedGoogle Scholar
  25. Mehlin C, Boni E, Buckner FS, Engel L, Feist T, Gelb MH, Haji L, Kim D, Liu C, Mueller N, Myler PJ, Reddy JT, Sampson JN, Subramanian E, Van Voorhis WC, Worthey E, Zucker F, Hol WGJ: Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. Mol Biochem Parasitol. 2006, 148: 144-160. 10.1016/j.molbiopara.2006.03.011.View ArticlePubMedGoogle Scholar
  26. De Marco A: Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli. Microb Cell Fact. 2009, 8: 26-10.1186/1475-2859-8-26.PubMed CentralView ArticlePubMedGoogle Scholar
  27. Crosnier C, Wanaguru M, McDade B, Osier FH, Marsh K, Rayner JC, Wright GJ: A library of functional recombinant cell-surface and secreted P. falciparum merozoite proteins. Mol Cell Proteomics. 2013, 12: 3976-3986. 10.1074/mcp.O113.028357.PubMed CentralView ArticlePubMedGoogle Scholar
  28. Sonnhammer EL, von Heijne G, Krogh A: A hidden Markov model for predicting transmembrane helices in protein sequences. Proc Int Conf Intell Syst Mol Biol. 1998, 6: 175-182.PubMedGoogle Scholar
  29. Eisenhaber B, Bork P, Eisenhaber F: Prediction of potential GPI-modification sites in proprotein sequences. J Mol Biol. 1999, 292: 741-758. 10.1006/jmbi.1999.3069.View ArticlePubMedGoogle Scholar
  30. Petersen TN, Brunak S, von Heijne G, Nielsen H: SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat Methods. 2011, 8: 785-786. 10.1038/nmeth.1701.View ArticlePubMedGoogle Scholar
  31. Dieckmann-Schuppert A, Bender S, Odenthal-Schnittler M, Bause E, Schwarz RT: Apparent lack of N-glycosylation in the asexual intraerythrocytic stage of Plasmodium falciparum. Eur J Biochem. 1992, 205: 815-825. 10.1111/j.1432-1033.1992.tb16846.x.View ArticlePubMedGoogle Scholar
  32. Crosnier C, Staudt N, Wright GJ: A rapid and scalable method for selecting recombinant mouse monoclonal antibodies. BMC Biol. 2010, 8: 76-10.1186/1741-7007-8-76.PubMed CentralView ArticlePubMedGoogle Scholar
  33. Sun Y, Gallagher-Jones M, Barker C, Wright GJ: A benchmarked protein microarray-based platform for the identification of novel low-affinity extracellular protein interactions. Anal Biochem. 2012, 424: 45-53. 10.1016/j.ab.2012.01.034.PubMed CentralView ArticlePubMedGoogle Scholar
  34. Durocher Y, Perret S, Kamen A: High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 2002, 30: E9-10.1093/nar/30.2.e9.PubMed CentralView ArticlePubMedGoogle Scholar
  35. Kerr JS, Wright GJ: Avidity-based extracellular interaction screening (AVEXIS) for the scalable detection of low-affinity extracellular receptor-ligand interactions. J Vis Exp. 2012, 7: e3881-Google Scholar
  36. Herscovitch M, Perkins E, Baltus A, Fan M: Addgene provides an open forum for plasmid sharing. Nat Biotechnol. 2012, 30: 316-317. 10.1038/nbt.2177.View ArticlePubMedGoogle Scholar
  37. Bushell KM, Söllner C, Schuster-Boeckler B, Bateman A, Wright GJ: Large-scale screening for novel low-affinity extracellular protein interactions. Genome Res. 2008, 18: 622-630. 10.1101/gr.7187808.PubMed CentralView ArticlePubMedGoogle Scholar
  38. Llinás M, Bozdech Z, Wong ED, Adai AT, DeRisi JL: Comparative whole genome transcriptome analysis of three Plasmodium falciparum strains. Nucleic Acids Res. 2006, 34: 1166-1173. 10.1093/nar/gkj517.PubMed CentralView ArticlePubMedGoogle Scholar
  39. Bozdech Z, Llinás M, Pulliam BL, Wong ED, Zhu J, DeRisi JL: The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum. PLoS Biol. 2003, 1: E5-PubMed CentralView ArticlePubMedGoogle Scholar
  40. Tham W-H, Healer J, Cowman AF: Erythrocyte and reticulocyte binding-like proteins of Plasmodium falciparum. Trends Parasitol. 2012, 28: 23-30. 10.1016/j.pt.2011.10.002.View ArticlePubMedGoogle Scholar
  41. Cowman AF, Crabb BS: Invasion of red blood cells by malaria parasites. Cell. 2006, 124: 755-766. 10.1016/j.cell.2006.02.006.View ArticlePubMedGoogle Scholar
  42. Aurrecoechea C, Brestelli J, Brunk BP, Dommer J, Fischer S, Gajria B, Gao X, Gingle A, Grant G, Harb OS, Heiges M, Innamorato F, Iodice J, Kissinger JC, Kraemer E, Li W, Miller JA, Nayak V, Pennington C, Pinney DF, Roos DS, Ross C, Stoeckert CJ, Treatman C, Wang H: PlasmoDB: a functional genomic database for malaria parasites. Nucleic Acids Res. 2009, 37 (Database issue): D539-D543.PubMed CentralView ArticlePubMedGoogle Scholar
  43. Punta M, Coggill PC, Eberhardt RY, Mistry J, Tate J, Boursnell C, Pang N, Forslund K, Ceric G, Clements J, Heger A, Holm L, Sonnhammer ELL, Eddy SR, Bateman A, Finn RD: The Pfam protein families database. Nucleic Acids Res. 2012, 40 (Database issue): D290-D301.PubMed CentralView ArticlePubMedGoogle Scholar
  44. Singh S, Soe S, Weisman S, Barnwell JW, Pérignon JL, Druilhe P: A conserved multi-gene family induces cross-reactive antibodies effective in defense against Plasmodium falciparum. PLoS One. 2009, 4: e5410-10.1371/journal.pone.0005410.PubMed CentralView ArticlePubMedGoogle Scholar
  45. Burgess BR, Schuck P, Garboczi DN: Dissection of merozoite surface protein 3, a representative of a family of Plasmodium falciparum surface proteins, reveals an oligomeric and highly elongated molecule. J Biol Chem. 2005, 280: 37236-37245. 10.1074/jbc.M506753200.View ArticlePubMedGoogle Scholar
  46. Kadekoppala M, Holder AA: Merozoite surface proteins of the malaria parasite: the MSP1 complex and the MSP7 family. Int J Parasitol. 2010, 40: 1155-1161. 10.1016/j.ijpara.2010.04.008.View ArticlePubMedGoogle Scholar
  47. Kadekoppala M, Ogun SA, Howell S, Gunaratne RS, Holder AA: Systematic genetic analysis of the Plasmodium falciparum MSP7-like family reveals differences in protein expression, location, and importance in asexual growth of the blood-stage parasite. Eukaryot Cell. 2010, 9: 1064-1074. 10.1128/EC.00048-10.PubMed CentralView ArticlePubMedGoogle Scholar
  48. Kadekoppala M, O’Donnell RA, Grainger M, Crabb BS, Holder AA: Deletion of the Plasmodium falciparum merozoite surface protein 7 gene impairs parasite invasion of erythrocytes. Eukaryot Cell. 2008, 7: 2123-2132. 10.1128/EC.00274-08.PubMed CentralView ArticlePubMedGoogle Scholar
  49. Miller SK, Good RT, Drew DR, Delorenzi M, Sanders PR, Hodder AN, Speed TP, Cowman AF, de Koning-Ward TF, Crabb BS: A subset of Plasmodium falciparum SERA genes are expressed and appear to play an important role in the erythrocytic cycle. J Biol Chem. 2002, 277: 47524-47532. 10.1074/jbc.M206974200.View ArticlePubMedGoogle Scholar
  50. Hu G, Cabrera A, Kono M, Mok S, Chaal BK, Haase S, Engelberg K, Cheemadan S, Spielmann T, Preiser PR, Gilberger T-W, Bozdech Z: Transcriptional profiling of growth perturbations of the human malaria parasite Plasmodium falciparum. Nat Biotechnol. 2010, 28: 91-98. 10.1038/nbt.1597.View ArticlePubMedGoogle Scholar
  51. Haase S, Cabrera A, Langer C, Treeck M, Struck N, Herrmann S, Jansen PW, Bruchhaus I, Bachmann A, Dias S, Cowman AF, Stunnenberg HG, Spielmann T, Gilberger T-W: Characterization of a conserved rhoptry-associated leucine zipper-like protein in the malaria parasite Plasmodium falciparum. Infect Immun. 2008, 76: 879-887. 10.1128/IAI.00144-07.PubMed CentralView ArticlePubMedGoogle Scholar
  52. Taylor TE, Molyneux ME, Wirima JJ, Borgstein A, Goldring JD, Hommel M: Intravenous immunoglobulin in the treatment of paediatric cerebral malaria. Clin Exp Immunol. 1992, 90: 357-362.PubMed CentralView ArticlePubMedGoogle Scholar
  53. Bustamante LY, Bartholdson SJ, Crosnier C, Campos MG, Wanaguru M, Nguon C, Kwiatkowski DP, Wright GJ, Rayner JC: A full-length recombinant Plasmodium falciparum Pf RH5 protein induces inhibitory antibodies that are effective across common Pf RH5 genetic variants. Vaccine. 2013, 31: 373-379. 10.1016/j.vaccine.2012.10.106.PubMed CentralView ArticlePubMedGoogle Scholar
  54. Wanaguru M, Crosnier C, Johnson S, Rayner JC, Wright GJ: Biochemical analysis of the Plasmodium falciparum Erythrocyte-Binding Antigen-175 (EBA175)-Glycophorin-A interaction: implications for vaccine design. J Biol Chem. 2013, 288: 32106-32117. 10.1074/jbc.M113.484840.PubMed CentralView ArticlePubMedGoogle Scholar
  55. Bartholdson SJ, Bustamante LY, Crosnier C, Johnson S, Lea S, Rayner JC, Wright GJ: Semaphorin-7A is an erythrocyte receptor for P. falciparum merozoite-specific TRAP homolog, MTRAP. PLoS Pathog. 2012, 8: e1003031-10.1371/journal.ppat.1003031.PubMed CentralView ArticlePubMedGoogle Scholar
  56. Taechalertpaisarn T, Crosnier C, Bartholdson SJ, Hodder AN, Thompson J, Bustamante LY, Wilson DW, Sanders PR, Wright GJ, Rayner JC, Cowman AF, Gilson PR, Crabb BS: Biochemical and functional analysis of two Plasmodium falciparum blood-stage 6-cys proteins: P12 and P41. PLoS One. 2012, 7: e41937-10.1371/journal.pone.0041937.PubMed CentralView ArticlePubMedGoogle Scholar
  57. Crosnier C, Bustamante LY, Bartholdson SJ, Bei AK, Theron M, Uchikawa M, Mboup S, Ndir O, Kwiatkowski DP, Duraisingh MT, Rayner JC, Wright GJ: Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature. 2011, 480: 534-537.PubMed CentralPubMedGoogle Scholar
  58. Muralidharan V, Oksman A, Pal P, Lindquist S, Goldberg DE: Plasmodium falciparum heat shock protein 110 stabilizes the asparagine repeat-rich parasite proteome during malarial fevers. Nat Commun. 2012, 3: 1310-PubMed CentralView ArticlePubMedGoogle Scholar
  59. Ntumngia FB, Bouyou-Akotet MK, Uhlemann A-C, Mordmüller B, Kremsner PG, Kun JFJ: Characterisation of a tryptophan-rich Plasmodium falciparum antigen associated with merozoites. Mol Biochem Parasitol. 2004, 137: 349-353. 10.1016/j.molbiopara.2004.06.008.View ArticlePubMedGoogle Scholar
  60. Chen L, Lopaticki S, Riglar DT, Dekiwadia C, Uboldi AD, Tham W-H, O’Neill MT, Richard D, Baum J, Ralph SA, Cowman AF: An EGF-like Protein Forms a Complex with Pf Rh5 and Is Required for Invasion of Human Erythrocytes by Plasmodium falciparum. PLoS Pathog. 2011, 7: e1002199-10.1371/journal.ppat.1002199.PubMed CentralView ArticlePubMedGoogle Scholar
  61. Douglas AD, Williams AR, Illingworth JJ, Kamuyu G, Biswas S, Goodman AL, Wyllie DH, Crosnier C, Miura K, Wright GJ, Long CA, Osier FH, Marsh K, Turner AV, Hill AVS, Draper SJ: The blood-stage malaria antigen Pf RH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun. 2011, 2 (May): 601-PubMed CentralView ArticlePubMedGoogle Scholar
  62. Hayton K, Gaur D, Liu A, Takahashi J, Henschen B, Singh S, Lambert L, Furuya T, Bouttenot R, Doll M, Nawaz F, Mu J, Jiang L, Miller LH, Wellems TE: Erythrocyte binding protein Pf RH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion. Cell Host Microbe. 2008, 4: 40-51. 10.1016/j.chom.2008.06.001.PubMed CentralView ArticlePubMedGoogle Scholar
  63. Baum J, Chen L, Healer J, Lopaticki S, Boyle M, Triglia T, Ehlgen F, Ralph SA, Beeson JG, Cowman AF: Reticulocyte-binding protein homologue 5 - an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum. Int J Parasitol. 2009, 39: 371-380. 10.1016/j.ijpara.2008.10.006.View ArticlePubMedGoogle Scholar

Copyright

© Zenonos et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement

Malaria Journal

ISSN: 1475-2875

Contact us